A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

Agouron Pharmaceuticals

Overview

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Cytomegalovirus Retinitis HIV Infections

Interventions

Nelfinavir mesylateDRUG

Eligibility

Sex: ALLMin age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * HIV infection. * Newly diagnosed or first progression of CMV retinitis. Exclusion Criteria Prior Medication: Excluded: Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.

Locations (8)

Univ of Southern California / LA County USC Med Cntr

Los Angeles, California, United States

Univ of California / UCI Med Ctr

Orange, California, United States

Univ of California / San Diego Treatment Ctr

San Diego, California, United States

Harbor UCLA Med Ctr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.